BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris
NCT ID: NCT01815450
Last Updated: 2015-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
369 participants
INTERVENTIONAL
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris
NCT01241331
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
NCT02604680
Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne
NCT00211523
Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne
NCT00211497
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
NCT00666900
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BLI1100
BLI1100 topical cream
BLI1100
BLI1100 topical cream
BLI1100 - modified formulation
BLI1100 topical cream
BLI1100 - modified formulation
BLI1100 topical cream
Placebo
Topical cream
Placebo
Placebo topical cream
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BLI1100
BLI1100 topical cream
BLI1100 - modified formulation
BLI1100 topical cream
Placebo
Placebo topical cream
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Qualifying Investigator's Global Assessment severity score
* Qualifying number of non-inflammatory lesions
* Qualifying number of inflammatory lesions
Exclusion Criteria
* Using medications that are reported to exacerbate acne
* Any clinically relevant finding at their baseline physical examination or dermatological medical history such as severe systemic diseases or diseases of the facial skin
* Have a known hypersensitivity or previous allergic reaction to any of the components
* Patients who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
* Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures
12 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Braintree Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John McGowan, MPH
Role: STUDY_DIRECTOR
Braintree Laboratories, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Dermatology Clincal Research
Fremont, California, United States
North Florida Dermatology Associates
Jacksonville, Florida, United States
Ameriderm Research
Ormond Beach, Florida, United States
Peachtree Dermatology Associates Research Center
Atlanta, Georgia, United States
The Indiana Clinical Trials Center
Plainfield, Indiana, United States
Great Lakes Research Group, Inc.
Bay City, Michigan, United States
Minnesota Clinical Study Center
Fridley, Minnesota, United States
Academic Dermatology Associates
Albuquerque, New Mexico, United States
Clinical Partners
Johnston, Rhode Island, United States
DiscoveResearch
Bryan, Texas, United States
Suzanne Bruce and Associates
Houston, Texas, United States
Dermatology Research Center
Salt Lake City, Utah, United States
The Education and Research Foundation
Lynchburg, Virginia, United States
Women's Clinical Research Center
Seattle, Washington, United States
Premier Clinical Research
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BLI1100-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.